文献速递肿瘤 PET/CT

双低活度一站式[18F]FDG与[68Ga]Ga-DOTA-FAPI-04全身PET/CT检查的可行性研究

One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-27

19例恶性肿瘤患者接受一站式双低活度[18F]FDG(0.37 MBq/kg)与[68Ga]Ga-DOTA-FAPI-04(0.925 MBq/kg)双示踪剂PET/CT,单次诊断CT生成PET/CT。双示踪剂PETD50-60较单PETFDG检出更多转移灶(491 vs. 261,P < 0.001)且病灶TNR更高,视觉评分更高(111 vs. 10),初诊患者44.4%肿瘤分期上调,再分期患者检出更多复发灶(68 vs. 7)。结论认为该方案结合两种示踪剂优势,扫描时间更短、辐射更低,临床可行。

要点

  • 双低活度一站式双示踪剂PET/CT在初诊患者中使44.4%肿瘤分期上调。
  • PETD50-60较PETFDG检出更多转移灶(491 vs. 261,P < 0.001)且TNR更高。
  • 每患者有效剂量26.2 ± 2.57 mSv,等于单次标准全身PET/CT。

核心结论

  • 一站式双示踪剂双低活度PET成像方案结合了[18F]FDG与[68Ga]Ga-DOTA-FAPI-04的优势,扫描时间更短、辐射更低,因而临床可行。

研究设计与样本

  • 19例恶性肿瘤患者接受一站式[18F]FDG(0.37 MBq/kg)PET(PETFDG),随后追加注射[68Ga]Ga-DOTA-FAPI-04(0.925 MBq/kg),在30-40分钟和50-60分钟分别行双示踪剂PET(PETD30-40和PETD50-60),并以单次诊断CT生成PET/CT。

主要发现

  • 双示踪剂PETD50-60与PETD30-40在检测原发肿瘤方面表现相似,但病灶TNR均显著高于PETFDG。
  • PETD50-60较PETFDG检出显著更多且TNR更高的转移灶(491 vs. 261,P < 0.001)。
  • 双示踪剂PETD50-60在显示原发肿瘤(12 vs. 2)和转移灶(99 vs. 8)方面的视觉评分显著高于单PETFDG(111 vs. 10)。
  • PETD50-60与PETD30-40之间的上述差异不显著。
  • 初诊患者中44.4%出现肿瘤分期上调;再分期患者中PETD50-60和PETD30-40均较PETFDG检出更多复发灶(68 vs. 7)。

关键数值与推荐

  • 病灶检出率与肿瘤/正常组织比值(TNR)在PETFDG/CT与PETD50-60/CT之间、以及PETD50-60/CT与PETD30-40/CT之间进行比较。
  • 建立视觉评分系统比较病灶可检测性。
  • PETD50-60较PETFDG检出转移灶491 vs. 261(P < 0.001)。
  • 视觉评分PETD50-60 vs. PETFDG为111 vs. 10(原发肿瘤12 vs. 2,转移灶99 vs. 8)。
  • 初诊患者肿瘤分期上调44.4%;再分期患者复发灶检出68 vs. 7。

临床怎么用

  • 原文结论认为该一站式双示踪剂双低活度PET成像方案临床可行(clinically applicable)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Positron emission tomography/computed tomography (PET/CT) based on fibroblast activation protein inhibitors (FAPI) has shown complementary values to 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) in cancer imaging. This study aimed to investigate the feasibility of a one-stop FDG-FAPI dual-tracer imaging protocol with dual-low activity for oncological imaging. METHODS: Nineteen patients with malignancies underwent one-stop [18F]FDG (0.37 MBq/kg) PET (PETFDG) and dual-tracer PET 30-40 and 50-60 min (hereafter, PETD30-40 and PETD50-60, respectively) after additional injection of [68Ga]Ga-DOTA-FAPI-04 (0.925 MBq/kg), with a single diagnostic CT to generate the PET/CT. The lesion detection rate and tumor-to-normal ratios (TNRs) of tracer uptake were compared between PETFDG/CT and PETD50-60/CT and between PETD50-60/CT and PETD30-40/CT. In addition, a visual scoring system was established to compare the lesion detectability. RESULTS: The dual-tracer PETD50-60 and PETD30-40/CT showed similar performance in detecting primary tumors but presented significantly higher lesion TNRs than PETFDG. Significantly, more metastases with higher TNRs were identified on PETD50-60 than PETFDG (491 vs. 261, P < 0.001). The dual-tracer PETD50-60 received significantly higher visual scores than single PETFDG (111 vs. 10) in demonstrating both primary tumors (12 vs. 2) and metastases (99 vs. 8). However, these differences were not significant between PETD50-60 and PETD30-40. These resulted in tumor upstaging in 44.4% patients taking PET/CT for initial assessment, and more recurrences (68 vs. 7) were identified in patients taking PET/CT for restaging, both on PETD50-60 and PETD30-40, compared to PETFDG. The reduced effective dosimetry per patient (26.2 ± 2.57 mSv) was equal to that of a single standard whole-body PET/CT. CONCLUSION: The one-stop dual-tracer dual-low-activity PET imaging protocol combines the strengths of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 with shorter duration and lesser radiation and is thus clinically applicable.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu G, Mao W, Yu H, et al. One-stop [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. Eur J Nucl Med Mol Imaging. 2023. PMID: 36971806. doi:10.1007/s00259-023-06207-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。